



Canadian
Cancer Clinical
Trials Network

Canadian Cancer Clinical Trials Network

Quarter Performance Report


Quarter 3 2016/17: October 1 – December 31, 2016


Table of Contents

| | |
|---|----|
| Section A: Progress at Adult Network Sites | 2 |
| Section B: Progress at Pediatric Network Sites..... | 12 |
| Section C: Portfolio Efficiency..... | 20 |
| Section D: Other metrics..... | 20 |
| Appendix: Additional Notes..... | 21 |

Section A: Progress at Adult Network Sites

Objective: To improve patient access to academic clinical trials: a) Improve adult patient recruitment by greater than 50% within four years



| | Actual | Target | Difference |
|------------------|--------|--------|---|
| Accrual | 872 | 842 | 31 |
| % above baseline | 142% | 137.5% |  |

Notes:

- 872 patients were recruited to adult Portfolio trials in Quarter 3 2016/17.
- The Network recruitment target for 2016-2017 is 37.5% above baseline. The quarterly Network target for 2016/17 is 842 patients recruited to meet an annual target of 3255 patients recruited.
- Data include adult sites with formal Agreements with 3CTN (N=47).
- The Network target is the target recruitment per year, as defined in the 3CTN business plan. The site target is the target recruitment per year as defined in the Agreement between 3CTN and sites.
- New Brunswick sites have not reported in year 3.
- 39 out of 47 adult sites exceeded their quarter baseline and 29 out of 47 adult sites exceeded their quarter target.
- Legend:




| | |
|---|--|
|  | below quarter baseline |
|  | exceed quarter baseline and above target |

Figure 2. Number of patients recruited to adult Network sites per region in Q3 2016/17



| | Manitoba | Atlantic Canada | Alberta | Quebec* | British Columbia | Ontario |
|----------------------------|----------|-----------------|---------|---------|------------------|---------|
| 2016/17 Quarterly Baseline | 25 | 29 | 45 | 137 | 47 | 404 |
| Y3Q3 Actual | 26 | 23 | 59 | 135 | 53 | 576 |

Figure 3. Number of patients recruited to adult Network sites per local-regional node (NCC + NACC) in Q3 2016/17




Figure 4. Progress to quarterly recruitment baseline at adult Network sites per region in Q3 2016/17




Figure 5. Percentage of patients recruited to quarter baseline of adult Network sites per local-regional node (NCC + NACC) in Q3 2016/17





Table 1. Number of patients recruited per adult Network site

| Network Site | **Y3 Baseline | Q3 2014 | Q4 2015 | Q1 2015 | Q2 2015 | Q3 2015 | Q4 2015 | Y2 Total | Q1 2016 | Q2 2016 | Q3 2016 | Y3 YTD Total | % of Y3 baseline |
|--|------------------|---------|---------|---------|---------|---------|---------|----------|---------|---------|---------|-----------------|---------------------|
| London Regional Cancer Program | 186 | 37 | 35 | 53 | 36 | 46 | 36 | 171 | 51 | 40 | 34 | 125 | 67% |
| Grand River Regional Cancer Centre | 20 | 6 | 6 | 1 | 4 | 5 | 3 | 13 | 16 | 11 | 12 | 39 | 195% |
| Windsor Regional Hospital | 14 | 4 | 4 | 4 | 3 | 5 | 5 | 17 | 12 | 29 | 15 | 56 | 400% |
| Juravinski Cancer Centre | 181 | 51 | 59 | 70 | 63 | 50 | 48 | 231 | 64 | 57 | 53 | 174 | 96% |
| Niagara Health System | 17 | 2 | 2 | 6 | 8 | 3 | 5 | 22 | 2 | 6 | 4 | 12 | 71% |
| Cambridge Memorial Hospital | 11 | 1 | 1 | 2 | 0 | 0 | 0 | 2 | 2 | 2 | 0 | 4 | 36% |
| St. Joseph Healthcare Hamilton* | 21 | - | - | - | - | - | 30 | 30 | 8 | 14 | 16 | 38 | 181% |
| Sunnybrook Research Institute | 141 | 50 | 63 | 78 | 58 | 39 | 56 | 231 | 94 | 78 | 99 | 271 | 192% |
| North York General Hospital | 0 | 1 | 2 | 0 | 0 | 1 | 3 | 4 | 2 | 1 | 4 | 7 | NA |
| Toronto East General Hospital | 2 | 0 | 0 | 2 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0% |
| Humber River Hospital | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 2 | 0 | 1 | 0 | 1 | NA |
| Princess Margaret Cancer Centre | 396 | 86 | 66 | 82 | 83 | 110 | 105 | 380 | 146 | 129 | 120 | 395 | 100% |
| Northeast Cancer Centre - Health Sciences North | 24 | 0 | 2 | 3 | 5 | 2 | 7 | 17 | 1 | 2 | 2 | 5 | 21% |
| Trillium Health Partners | 27 | 2 | 3 | 1 | 4 | 0 | 0 | 5 | 7 | 28 | 10 | 45 | 167% |
| Thunder Bay Regional Health Sciences Centre | 26 | 2 | 0 | 1 | 0 | 1 | 1 | 3 | 17 | 11 | 9 | 37 | 142% |
| Southlake Regional Health Centre | 10 | 0 | 1 | 3 | 2 | 2 | 8 | 15 | 17 | 32 | 18 | 67 | 670% |
| Royal Victoria Hospital | 8 | 6 | 2 | 7 | 2 | 4 | 5 | 18 | 15 | 22 | 8 | 45 | 563% |
| St. Michael's Hospital | 19 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 6 | 0 | 7 | 37% |
| William Osler Health System | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 8 | 11 | 29 | 2900% |
| Markham Stouffville Hospital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 7 | 0 | 17 | NA |
| Mount Sinai Hospital* | 21 | - | - | - | - | 6 | 6 | 12 | 17 | 12 | 5 | 34 | 162% |
| The Ottawa Hospital | 132 | 35 | 29 | 54 | 51 | 72 | 61 | 238 | 86 | 85 | 110 | 281 | 213% |
| Kingston General Hospital | 41 | 17 | 7 | 12 | 11 | 11 | 24 | 58 | 33 | 29 | 39 | 101 | 246% |
| Lakeridge Health | 22 | 4 | 2 | 4 | 9 | 3 | 10 | 26 | 24 | 24 | 7 | 55 | 250% |
| CancerCare Manitoba | 99 | 17 | 21 | 26 | 14 | 18 | 14 | 72 | 30 | 21 | 26 | 77 | 78% |
| Saint John Regional Hospital | 37 | 5 | 6 | 2 | 3 | 3 | 8 | 16 | - | - | - | 0 | 0% |
| Dr. Everett Chalmers Hospital | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | - | - | 1 | 100% |
| Dr. Léon-Richard Oncology Centre | 9 | 1 | 1 | 0 | 1 | 1 | 2 | 4 | 2 | 1 | 0 | 3 | 33% |
| Nova Scotia Health Authority | 39 | 1 | 3 | 14 | 9 | 4 | 4 | 31 | 16 | 9 | 13 | 38 | 97% |
| PEI Cancer Treatment Centre | 8 | 0 | 1 | 4 | 4 | 0 | 0 | 8 | 0 | 0 | 2 | 2 | 25% |
| Nova Scotia Health Authority, Hematology | 7 | 7 | 5 | 14 | 4 | 1 | 6 | 25 | 7 | 4 | 5 | 16 | 229% |
| Eastern Regional Health Authority (NFL) | 15 | | | | | | | | 0 | 1 | 3 | 4 | 27% |
| BC Cancer Agency - Vancouver Centre | 106 | 33 | 28 | 27 | 30 | 28 | 24 | 109 | 34 | 41 | 29 | 104 | 98% |
| Abbotsford Centre | 16 | 5 | 7 | 7 | 5 | 10 | 6 | 28 | 6 | 3 | 3 | 12 | 75% |
| Centre for the North, Prince George | 1 | 2 | 1 | 0 | 1 | 1 | 3 | 5 | 0 | 1 | 2 | 3 | 300% |
| Sindi Ahluwalia Hawkins Centre for the Southern Inte | 38 | 10 | 17 | 9 | 11 | 10 | 8 | 38 | 14 | 7 | 4 | 25 | 66% |
| Vancouver Island Centre | 26 | 4 | 5 | 12 | 4 | 12 | 14 | 42 | 14 | 21 | 15 | 50 | 192% |

| Network Site | **Y3 Baseline | Q3 2014 | Q4 2015 | Y1 Total | Q1 2015 | Q2 2015 | Q3 2015 | Q4 2015 | Y2 Total | Q1 2016 | Q2 2016 | Q3 2016 | Y3 YTD Total | % of Y3 baseline |
|---|------------------|------------|------------|-------------|------------|------------|------------|------------|-------------|-------------|-------------|------------|-----------------|---------------------|
| McGill University Health Centre (MUHC)*** | - | - | - | 0 | - | - | - | - | - | - | - | - | 0 | NA |
| CIUSSS de l'Ouest-de-l'Île-de-Montréal(CIUSSS ODIM)* | - | - | - | 0 | - | - | - | - | - | - | - | - | 0 | NA |
| CIUSSS du Centre-Ouest-de-l'Île-de-Montréal(CIUSSS CODIM)* | 87 | - | - | 0 | - | - | 30 | 41 | 71 | 40 | 34 | 41 | 115 | 132% |
| CISSS de l'Outaouais* | 3 | - | - | 0 | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0% |
| CHU de Québec – Université Laval* | 180 | - | - | 0 | - | - | 8 | 2 | 10 | 27 | 28 | 22 | 77 | 43% |
| CISSS du Bas-Saint-Laurent(CISSS-BSL)* | 4 | - | - | 0 | - | - | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 50% |
| Institut universitaire de cardiologie et de pneumologie de Québec (IUCPQ)*** | - | - | - | 0 | - | - | - | - | - | - | - | - | 0 | NA |
| CIUSSS de l'Estrie – Centre hospitalier universitaire de Sherbrooke (CIUSSS-Estrie-CHUS)* | 46 | - | - | 0 | - | - | 7 | 9 | 16 | 12 | 13 | 18 | 43 | 93% |
| CISSS de Chaudière-Appalaches(CISSS CA)*** | - | - | - | 0 | - | - | - | - | - | - | - | - | 0 | NA |
| Centre Hospitalier de l'Université de Montréal (CHUM)* | 153 | - | - | 0 | - | - | 25 | 34 | 59 | 49 | 39 | 32 | 120 | 78% |
| CIUSSS de la Mauricie-et-du-Centre-du-Québec (CIUSSS MCQ) * | 8 | - | - | 0 | - | - | 1 | 0 | 1 | 3 | 6 | 5 | 14 | 175% |
| CISSS de Laval* | 4 | - | - | 0 | - | - | 2 | 1 | 3 | 1 | 2 | 4 | 7 | 175% |
| CIUSSS du Nord-de-l'Île-de-Montréal(CIUSSS NDIM)* | 3 | - | - | 0 | - | - | 0 | 0 | 0 | 0 | 3 | 0 | 3 | 100% |
| CIUSSS de l'Est-de-l'Île-de-Montréal(CIUSSS-EDIM)* | 60 | - | - | 0 | - | - | 5 | 7 | 12 | 8 | 10 | 11 | 29 | 48% |
| Tom Baker Cancer Centre | 76 | 31 | 10 | 41 | 41 | 35 | 34 | 30 | 140 | 28 | 35 | 33 | 96 | 126% |
| Cross Cancer Institute | 102 | 26 | 25 | 51 | 11 | 30 | 28 | 44 | 113 | 45 | 42 | 26 | 113 | 111% |
| Total (N=64 in Y3, 65 in Y2 & 53 sites for Y1) | 2795 | 537 | 492 | 1029 | 630 | 572 | 678 | 778 | 2658 | 1081 | 1039 | 942 | 3062 | 110% |
| Adult Patient Sites (N=49 for Y3, 48 for Y2, and 36 for Y1) | 2448 | 449 | 416 | 865 | 551 | 491 | 588 | 670 | 2300 | 972 | 955 | 872 | 2799 | 114% |
| Ped sites (N=17) total | 347 | 88 | 76 | 164 | 79 | 81 | 90 | 108 | 358 | 109 | 84 | 70 | 263 | 76% |

Objective: To demonstrate impact of the Network and academic trials on the Canadian Health Care System: a) Develop and maintain a portfolio of academic trials that will ensure the enthusiastic participation of academic trialists and patients and impact patient care.


Figure 6. Total Portfolio trials at adult Network sites per quarter, Q4 2014/15 - Q3 2016/17



Notes:


- There were 184 Portfolio trials in 2016, (YTD Total =3 newly added+11 closed YTD +170 previous recruiting trials)
- 3 news trials are included in the 173 recruiting trials at the end of Quarter 3
- Three trials were available at both adult and pediatric Network sites in 2016 and are included in both adult and pediatric figures

Figure 7. Breakdown of Portfolio trials at adult Network sites as of February 23, 2016



- The data provided in Figure 7 are a snapshot of the Portfolio as of Feb. 23, 2017 (n=184)

Figure 8. Breakdown of personalized medicine trials at adult Network sites for 2016/2017 Portfolio Trials




Notes:

- 74 Personalized medicine trials open to recruitment at adult Network sites, as of Feb. 24, 2017 (n=184)
- 40% of all trials at adult Network sites have a personalized medicine component
- Three trials were available at both adult and pediatric Network sites in 2016 and are included in both adult and pediatric figures
- There were 21 out of 184 (11%) immunotherapy related trials.

| Category | Definition |
|--------------------------------|---|
| Patient eligibility | Use of a genetic marker or other individualized biologic factor to determine if patient is eligible for the trial (i.e. included in trial design via the inclusion/exclusion criteria) |
| Study endpoint | Use of a genetic marker or other individualized biologic factor to correlate with study endpoint (i.e. included in trial design as an objective or endpoint) |
| Stratify into different groups | After patient enrollment, trial design uses a genetic marker or other individualized biologic factor to stratify into different groups (i.e. included in trial design to stratify for treatment or analysis groups) |
| Targeted therapy | Trial is using a molecular targeted therapy; drug used in a “targeted” patient population (i.e. HER2+ breast cancer gets a HER2 targeted agent) |

Figure 9. Breakdown of Portfolio trials at adult Network centres by lead country for 2016/2017
Portfolio Trials




Notes:

- Breakdown of trials at adult Network sites by lead country, as of February 23, 2017 (n=184)
- Approx. 63% of all trials at adult Network sites are led by Canada – 6% of which are international, multicentered studies
- The average number of Network sites per trial is 5.78.
- Three trials were available at both adult and pediatric Network sites in 2016 and are included in both adult and pediatric figures


Section B: Progress at Pediatric Network Sites

Objective: To improve patient access to academic clinical trials: Improve recruitment of pediatric patients



Notes:

- 70 patients were recruited to Portfolio trials at pediatric Network sites in Quarter 3 2016/17. The quarterly target for 2015/16 is 113 patients recruited to meet an annual target of 451 patients recruited. Pediatric Network sites are 4% below its quarterly target for recruitment
- Data includes pediatric sites associated with the C17 Council (n=17)
- Please note that the baseline of C17 was re-calculated due to removal of an ineligible trial in the baseline.
- Legend:

| | |
|---|---------------------------|
|  | lower than quarter target |
|---|---------------------------|


| | Accrual | Target | Difference |
|------------------|---------|--------|---|
| Accrual | 70 | 113 | 43 |
| % above baseline | 80% | 130% |  |

Figure 11. Number of patients recruited per pediatric Network site in Q3 2016/17




Figure 12. Progress to quarter baseline recruitment per pediatric Network site in Q3 2016/17





Table 2. Number of patients recruited per pediatric Network site

| Network Site | **Y3 Baseline | Q3 2014 | Q4 2015 | Y1 Total | Q1 2015 | Q2 2015 | Q3 2015 | Q4 2015 | Q1 2016 | Q2 2016 | Q3 2016 | Y3 YTD Total | % of Y3 baseline |
|--|------------------|------------|------------|-------------|------------|------------|------------|------------|-------------|-------------|------------|-----------------|---------------------|
| C17 (national pediatric total) | 347 | 88 | 76 | 164 | 79 | 81 | 90 | 108 | 109 | 84 | 70 | 263 | 76% |
| The Hospital for Sick Children | 91 | 29 | 21 | 50 | 22 | 23 | 25 | 39 | 29 | 20 | 16 | 65 | 71% |
| CHU Sainte-Justine | 42 | 9 | 9 | 18 | 10 | 1 | 8 | 7 | 14 | 10 | 8 | 32 | 76% |
| BC Children's Hospital | 34 | 9 | 4 | 13 | 7 | 12 | 11 | 16 | 9 | 12 | 4 | 25 | 74% |
| Montreal Children's Hospital | 24 | 3 | 6 | 9 | 4 | 5 | 8 | 6 | 6 | 1 | 2 | 9 | 38% |
| Alberta Children's Hospital | 21 | 5 | 5 | 10 | 8 | 7 | 3 | 3 | 3 | 5 | 0 | 8 | 38% |
| McMaster/Hamilton Health Sciences Centre | 14 | 4 | 2 | 6 | 4 | 7 | 2 | 7 | 10 | 2 | 3 | 15 | 107% |
| Children's Hospital of Eastern Ontario | 20 | 5 | 5 | 10 | 5 | 4 | 3 | 6 | 7 | 8 | 13 | 28 | 140% |
| Children's Hospital, London Health Sciences Centre | 12 | 3 | 4 | 7 | 2 | 6 | 5 | 2 | 5 | 9 | 5 | 19 | 158% |
| Stollery Children's Hospital | 11 | 4 | 4 | 8 | 3 | 2 | 2 | 3 | 10 | 7 | 6 | 23 | 209% |
| IWK Health Centre | 20 | 4 | 2 | 6 | 6 | 2 | 8 | 4 | 6 | 1 | 2 | 9 | 45% |
| CHU de Quebec | 17 | 4 | 3 | 7 | 2 | 3 | 7 | 2 | 0 | 3 | 2 | 5 | 29% |
| CancerCare Manitoba | 18 | 1 | 4 | 5 | 2 | 4 | 6 | 8 | 3 | 4 | 3 | 10 | 56% |
| Saskatoon Cancer Centre | 6 | 5 | 4 | 9 | 2 | 1 | 0 | 3 | 2 | 1 | 2 | 5 | 83% |
| Janeway Child Health Centre | 4 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 2 | 0 | 2 | 4 | 100% |
| Kingston General Hospital | 9 | 2 | 3 | 5 | 1 | 3 | 1 | 2 | 3 | 1 | 2 | 6 | 67% |
| Allan Blair Cancer Centre | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0% |
| CHU de Sherbrooke | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | NA |
| Total (N=64 in Y3, 65 in Y2 & 53 sites for Y1) | 2795 | 537 | 492 | 1029 | 630 | 572 | 678 | 778 | 1081 | 1039 | 942 | 3062 | 110% |
| Adult Patient Sites (N=49 for Y3, 48 for Y2, and 36 for Y1) | 2448 | 449 | 416 | 865 | 551 | 491 | 588 | 670 | 972 | 955 | 872 | 2799 | 114% |
| Ped sites (N=17) total | 347 | 88 | 76 | 164 | 79 | 81 | 90 | 108 | 109 | 84 | 70 | 263 | 76% |

Objective: To demonstrate impact of the Network and academic trials on the Canadian Health Care System: a) Develop and maintain a portfolio of academic trials that will ensure the enthusiastic participation of academic trialists and patients and impact patient care.

**Figure 13. Total Portfolio trials at pediatric Network sites per quarter
Q4 2014/15 - Q3 2016/17**



Notes:

- There were 43 Portfolio trials available at pediatric Network sites, 1 new trials added at the end of Quarter 3
- The data provided in Figure 13 is a snapshot of the Portfolio as of Feb. 23, 2017
- Three trials were available at both adult and pediatric Network sites in 2016 and is included in both adult and pediatric figures

Figure 14. Breakdown of 2016 Portfolio trials at pediatric Network sites





Figure 15. Breakdown of personalized medicine trials at pediatric Network sites in fiscal year 2016/2017




Notes:

- 22 Personalized medicine trials at pediatric Network sites, as of February 23, 2017 (n=43)
- 51% of all trials at pediatric Network sites have a personalized medicine component
- Three trials were available at both adult and pediatric Network sites in 2016 and are included in both adult and pediatric figures
- There were 8 out of 43 trials (19%) that immunotherapy related trials.

| Category | Definition |
|--------------------------------|---|
| Patient eligibility | Use of a genetic marker or other individualized biologic factor to determine if patient is eligible for the trial (i.e. included in trial design via the inclusion/exclusion criteria) |
| Study endpoint | Use of a genetic marker or other individualized biologic factor to correlate with study endpoint (i.e. included in trial design as an objective or endpoint) |
| Stratify into different groups | After patient enrollment, trial design uses a genetic marker or other individualized biologic factor to stratify into different groups (i.e. included in trial design to stratify for treatment or analysis groups) |
| Targeted therapy | Trial is using a molecular targeted therapy; drug used in a “targeted” patient population (i.e. HER2+ breast cancer gets a HER2 targeted agent) |

Figure 16. Breakdown of Portfolio trials at pediatric Network centres by lead country, in 2016/2017



Notes:

- Breakdown of trials at pediatric Network sites by lead country, as of Feb.23, 2017 (n=43)
- 18% of all trials at pediatric Network sites are led by Canada – 2% of which are international, multicentered studies
- The average number of Network sites per trial is 7.65.
- Three trials were available at both adult and pediatric Network sites in 2016 and are included in both adult and pediatric figures

Section C: Portfolio Efficiency

Objective: To improve patient access and increase in successful completion of trials

Portfolio approval process timeline:

| Calendar Year | # Application Completed | Average Application Processing Time (days) |
|---------------|-------------------------|--|
| 2015 | 89 | 24 |
| 2016 | 69 | 23 |

| Calendar Year | # Application Completed | Average FPR Time (days) |
|---------------|-------------------------|-------------------------|
| 2015 | 6 | 47 |
| 2016 | 10 | 94 |

Note: 1) from application received to approve/decline the application since Jan 13, 2015 to December 2016; 2) from date site agreed to pursue peer review to date last reviewer submitted completed peer review package to 3CTN (approved as peer reviewed).

Section D: Other metrics

Objective: To provide overall metrics to all sites.

Complexity mix by number of total portfolio trials and patients accrued.

| Patient Scope | Low | | Standard | | High | |
|----------------|-------------|-----------------|-------------|-----------------|-------------|-----------------|
| | # of trials | Accrual (total) | # of trials | Accrual (total) | # of trials | Accrual (total) |
| Overall | 26% | 41% | 60% | 44% | 14% | 15% |
| Adults | 30% | 42% | 61% | 46% | 9% | 12% |
| Peds | 23% | 27% | 53% | 18% | 23% | 55% |

*total data updated Feb. 23, 2017

Site efficiency - National

| Region | Activation Timeline from NOL/Sponsor Approval/Central Approval to Site Open to Accrual * | Local Site REB Processing Time (site submission to approval) | Local Site REB Approval to First Patient Recruited | Site Open to Accrual to First Patient Recruited** | Recruiting Period (from open to closed to accrual) | Site Accrual vs. Site Target |
|--------------------------------|--|--|--|---|--|------------------------------|
| Peds | 216 | - | 177 | 197 | 824 | 151% |
| National (adult network sites) | 262 | 64 | 173 | 91 | 371 | 64% |

Note:

- Peds used NOL, most sites used "sponsor approval"
- first patients of peds and Alberta are by month and not exact dates
- under setup trials not included
- only for portfolio start date greater than April 1, 2014 and site open greater than April 1, 2014
- Due to various available data, the above metrics are for references only.

Appendix: Additional Notes

Table 3. Reporting periods and dates Q4 2014/15 – Q3 2016/17

| Quarter | Period | Recruitment Database Lock |
|------------|-------------------------|---------------------------|
| Q3 2014/15 | October – December 2014 | NA* |
| Q4 2014/15 | January – March 2015 | NA* |
| Q1 2015/16 | April – June 2015 | NA* |
| Q2 2015/16 | July – September 2015 | October 20, 2015 |
| Q3 2015/16 | October – December 2015 | March 31, 2016 |
| Q4 2015/16 | January – March 2016 | May 31, 2016 |
| Q1 2016/17 | April – June 2016 | August 31, 2016 |
| Q2 2016/17 | July – September 2016 | November 15, 2016 |
| Q3 2016/17 | October – December 2016 | February 15, 2017 |

*Dates not available as database lock implemented in Q2 2015/16